An agreement has been signed between Bharat Biotech International Limited (BBIL) and BBio wherein BBIL will procure drug substances for the production of OPV to be supplied within India and globally.
New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on Sunday wooed Elon Musk to invest in India to manufacture Tesla electric cars, saying it will be the best investment he would have ever made. Musk, who has made a successful USD 44 billion acquisition bid for Twitter, had in the past asked India […]
Mumbai: The Pune-based Serum Institute of India (SII) will launch Covavax — its vaccine for children aged above 3 years — in the next six months, SII CEO Adar Poonawalla said here on Tuesday. Covavax is currently under trial and has shown excellent results down to the age of 3 years, Poonawalla said while addressing […]
"Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune," he shared in a tweet on Friday.
Amaravati: The Andhra Pradesh government on Saturday placed an order for purchase of 4.08 crore doses each of Covaxin and Covishield for vaccinating 2.04 crore people in the 18-45 age group from May 1. Government Principal Secretary (Covid Management and Vaccination) Muddada Ravichandra wrote letters to Bharat Biotech MD Krishna Yella and Serum Institute of […]
Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India. It has been tested against African and UK variants of COVID19 and has an overall efficacy of 89 per cent.
Poonawalla joined the Serum Institute of India in 2001 and became the CEO of Serum Institute with complete control of the day-to-day operations of the company in 2011.